Insulin aspart, recombinant Subcutaneous and Xpovio (100 MG Once Weekly)
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Xpovio (100 MG Once Weekly) and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: selinexor
Brand name: Xpovio
Synonyms: Xpovio
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Xpovio (60 MG Once Weekly)
- Insulin aspart, recombinant Subcutaneous-Xpovio (80 MG Once Weekly)
- Insulin aspart, recombinant Subcutaneous-Xpovio (80 MG Twice Weekly)
- Insulin aspart, recombinant Subcutaneous-Xryliderm
- Insulin aspart, recombinant Subcutaneous-Xrylix
- Insulin aspart, recombinant Subcutaneous-Xtampza ER
- Xpovio (100 MG Once Weekly)-Insulin degludec
- Xpovio (100 MG Once Weekly)-Insulin Degludec (U-100) Prefilled Pens
- Xpovio (100 MG Once Weekly)-Insulin Degludec (U-100) Vials
- Xpovio (100 MG Once Weekly)-Insulin Degludec (U-200) Prefilled Pens
- Xpovio (100 MG Once Weekly)-Insulin degludec and liraglutide
- Xpovio (100 MG Once Weekly)-Insulin degludec and liraglutide Subcutaneous